Panama’s Ministry of Health has formally installed a new Technical Council for Medical Cannabis. The move, executed this week, is a direct effort to strengthen the implementation of the country’s 2021 therapeutic cannabis law and improve patient access to regulated treatments.
The council’s establishment, mandated by Executive Decree 27 of 2025, creates a central governing body to oversee the nascent medical cannabis program. Officials stated the primary goal is to ensure safe, controlled, and quality-controlled access for Panamanian patients who qualify for this type of treatment.
Health Minister Fernando Boyd Galindo presided over the installation ceremony. He emphasized the patient-centric focus of the regulatory framework, which was originally established under Law 242.
“One of the main objectives of the law is to ensure the right of patients to receive this type of treatment under strict medical standards,” Boyd Galindo said. [Translated from Spanish]
The council will begin its work immediately, holding regular monthly sessions to shape policy. Its formation follows tangible, though early, progress in Panama’s medical cannabis sector. The government has already issued three licenses for the manufacture of medicinal cannabis derivatives and approved one license for pharmacies, with other applications currently under evaluation.
Council Mandate and Key Responsibilities
Chaired by Eric Conte, the Technical Council for Medical Cannabis carries a broad mandate. Its responsibilities are designed to build a comprehensive regulatory ecosystem from the ground up. The body will develop educational and social policies while reviewing all regulations concerning control, quality, and safety protocols.
It will also evaluate clinical guidelines and monitor importation, domestic production, and scientific research activities. A core function will be verifying and facilitating patient access to approved treatments. The council will further supervise the National Program for the Study and Medicinal Use of Cannabis, ensuring its objectives are met.
This structure aims to move past the initial hurdles of implementation. For patients and advocates, the council’s work is critical to untangling the bureaucratic delays that have characterized the rollout, a topic previously explored in reports on cannabis medicinal access challenges.
Multisectoral Composition for Balanced Oversight
The council’s composition reflects a deliberate, whole-of-government approach to regulation. It includes representatives from multiple ministries beyond health, including Public Security, Agricultural Development, and Commerce and Industries. The National Customs Authority and the Caja de Seguro Social (Panama), the country’s social security fund, also have seats at the table.
Critically, the body incorporates voices from patient advocacy groups and the scientific community. This inclusion is intended to balance regulatory oversight with practical patient needs and evidence-based decision-making. The diverse membership seeks to prevent siloed decision-making that could hinder the program’s effectiveness.
The Panama Ministry of Health often utilizes such cross-sector committees for complex health initiatives, similar to strategies seen in other public health mobilizations.
Projected Impact on Panama’s Health System
Ministry officials project significant systemic benefits from the council’s operations. They expect it to strengthen overall health governance and guarantee transparency across all medical cannabis processes. Ensuring consistent quality and safety standards for all products is another stated priority, as is promoting equitable access to treatments nationwide.
The successful integration of Medical Cannabis into the formal health system represents a modernizing shift for Panama. It signals a commitment to developing public health policies grounded in scientific evidence rather than stigma. The council now faces the practical task of translating legal frameworks into accessible therapies.
Its work will directly influence how quickly products reach pharmacies and patients. For many, this marks a pivotal step away from uncertainty and toward a regulated, hopeful future for therapeutic options in the country. The ministry has framed this as part of a broader push for patient-centered care, aligning with other recent administrative efforts to bolster health services.